Eterna Therapeutics (US:ERNA) — Company Overview, News & Financial Data
Eterna Therapeutics is a biotechnology firm working on innovative therapies and gene editing techniques to treat various diseases.
Eterna Therapeutics
Eterna Therapeutics (NASDAQ:ETRN) is a biotechnology firm that focuses on the development and innovation of therapies aimed at treating and potentially curing a variety of diseases. At the heart of their operations is a commitment to research and development, through which they are currently working on several promising projects, including advanced gene editing techniques. These initiatives highlight the company's objective to push the boundaries of medicine and provide groundbreaking solutions for patients worldwide. Eterna Therapeutics is dedicated to advancing healthcare and improving the lives of patients through scientific excellence and innovative treatments.
Snapshot
Operations
Products and/or services of Eterna Therapeutics
- mRNA platform technology aimed at developing vaccines and therapeutics.
- Gene editing tools for precision medicine in genetic disorders.
- In vivo delivery systems for targeted gene therapy applications.
- Collaboration on cancer immunotherapy treatments leveraging mRNA technology.
- Partnerships for the development of rare disease treatments using gene therapy.
- Research on aging and degenerative disease intervention through novel mRNA applications.
Eterna Therapeutics executive team
- Mr. Sanjeev LutherCEO, President & Director
- Ms. Sandra M. GurrolaPrincipal Financial & Accounting Officer and Senior VP of Finance
- Ms. Dorothy J. ClarkeGeneral Counsel
- Dr. Robert Hamilton Pierce M.D.Chief Scientific Officer
- Dr. Kanika Chawla Ph.D.Senior Vice President of Technical Operations (Consultant)